As neurologic findings among patients with COVID-19 emerge, comparison to sequelae seen with other coronaviruses is instructive.
AstraZeneca’s Investigational COVID-19 Prevention Drug Reduces Risk of Infection in Immunocompromised Persons
Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Donanemab FDA AdComm Hearing Scheduled for June 10, Eli Lilly Says
The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.
Distress Signals: How to Help a Clinician Colleague in Need
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.
Study: COVID-19 Booster Shots Elicit Longer Immunity than Primary Series Alone
Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.
RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose
Your daily dose of the clinical news you may have missed.